FDA
-
-
-
-
-
-
-
Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH
-
-
-
-
-
-
-
Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline
-
-
-
-
-
-
-
Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results
-
-
-
-
-
-
-
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates
-
-
-
-
-
-
-
H.C. Wainwright Starts Madrigal Pharmaceuticals (MDGL) at Buy
-
325,553 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

